ReviewImmunity, inflammation and disease2026
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer.
Review in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has revolutionized oncology, its efficacy remains constrained by the immunosuppressive tumor microenvironment (TME), off-target toxicity, and poor biodistribution of therapeutic agents.
objectiveThis review elucidates how engineered nanoparticles (NPs) are redefining immune-oncology by enabling the precise delivery of immunomodulators, antigens, and genetic payloads to target cells, while reprogramming the TME to convert "cold" tumors into immunogenic "hot" landscapes.
methodsA literature search was conducted using PubMed, Scopus, and Google Scholar. The review was performed in a narrative and non-systematic manner, focusing on studies addressing nanotechnology-enhanced cancer immunotherapy.
resultsWe dissect the physicochemical and functional versatility of NPs, emphasizing size-, charge-, and ligand-dependent strategies to enhance lymph node targeting, APC activation, and sustained cargo release. Innovations in metallic, lipid-based, and biomimetic NPs are highlighted, including gold and lipid-based NPs for enhanced immune responses. Furthermore, we explore combinatorial approaches, such as NP-mediated co-delivery of checkpoint inhibitors and chemotherapeutics, which amplify cytotoxic T-cell responses and mitigate systemic toxicity. Clinical advancements, including Nab-Paclitaxel and mRNA-loaded lipid NPs, underscore the translational potential of these platforms, with trials demonstrating improved survival and manageable adverse profiles.
conclusionHowever, challenges persist in optimizing targeting precision, scalability, and long-term safety. Integrating breakthroughs in material science, immunology, and bioengineering, this review charts a roadmap for next-generation nano-immunotherapies, advocating patient-specific designs and multimodal regimens. As the field strides toward clinical maturity, nanotechnology is poised to unlock the full potential of immunotherapy, paving the way for adaptive, immune-guided, and potentially curative cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.